Copyright © 2010 David Laurin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. C. H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer, “Childhood and adolescent lymphoid and myeloid leukemia,” Hematology, pp. 118–145, 2004.
2. A. W. Loren and D. L. Porter, “Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 41, no. 5, pp. 483–493, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. E. Biagi, V. Marin, G. M. P. G. Attianese, E. Dander, G. D'Amico, and A. Biondi, “Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies,” Haematologica, vol. 92, no. 3, pp. 381–388, 2007. View at Publisher · View at Google Scholar · View at Scopus
4. M. A. Pule, K. C. Straathof, G. Dotti, H. E. Heslop, C. M. Rooney, and M. K. Brenner, “A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells,” Molecular Therapy, vol. 12, no. 5, pp. 933–941, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. R. J. Brentjens, E. Santos, Y. Nikhamin, et al., “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clinical Cancer Research, vol. 13, no. 18, pp. 5426–5435, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. C. Roessig, S. P. Scherer, A. Baer, et al., “Targeting CD19 with genetically modified EBV-specific human T lymphocytes,” Annals of Hematology, vol. 81, supplement 2, pp. S42–S43, 2002. View at Scopus
7. L. J. N. Cooper, Z. Al-Kadhimi, L. M. Serrano, et al., “Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1,” Blood, vol. 105, no. 4, pp. 1622–1631, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. L. J. N. Cooper, M. S. Topp, L. M. Serrano, et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood, vol. 101, no. 4, pp. 1637–1644, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. C. Imai, S. Iwamoto, and D. Campana, “Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells,” Blood, vol. 106, no. 1, pp. 376–383, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. V. Marin, E. Dander, E. Biagi, et al., “Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy,” Experimental Hematology, vol. 34, no. 9, pp. 1219–1229, 2006. View at Scopus
11. M. Barry and R. C. Bleackley, “Cytotoxic T lymphocytes: all roads lead to death,” Nature Reviews Immunology, vol. 2, no. 6, pp. 401–409, 2002. View at Scopus
12. S. H. Kaufmann and D. P. Steensma, “On the TRAIL of a new therapy for leukemia,” Leukemia, vol. 19, no. 12, pp. 2195–2202, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. F. H. Igney and P. H. Krammer, “Death and anti-death: tumour resistance to apoptosis,” Nature Reviews Cancer, vol. 2, no. 4, pp. 277–288, 2002. View at Scopus
14. D. Chowdhury and J. Lieberman, “Death by a thousand cuts: granzyme pathways of programmed cell death,” Annual Review of Immunology, vol. 26, pp. 389–420, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. D. Kagi, B. Ledermann, K. Burki, et al., “Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice,” Nature, vol. 369, no. 6475, pp. 31–37, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. H. G. Otten, W. G. J. van Ginkel, A. Hagenbeek, and E. J. Petersen, “Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia,” Leukemia, vol. 18, no. 8, pp. 1401–1405, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. K. Uno, T. Inukai, N. Kayagaki, et al., “TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells,” Blood, vol. 101, no. 9, pp. 3658–3667, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
18. K. Clodi, D. Wimmer, Y. Li, et al., “Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells,” British Journal of Haematology, vol. 111, no. 2, pp. 580–586, 2000.
19. A. Hombach, H. Kohler, G. Rappl, and H. Abken, “Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor,” Journal of Immunology, vol. 177, no. 8, pp. 5668–5675, 2006. View at Scopus
20. M. R. Betts, J. M. Brenchley, D. A. Price, et al., “Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation,” Journal of Immunological Methods, vol. 281, no. 1-2, pp. 65–78, 2003. View at Publisher · View at Google Scholar · View at Scopus
21. B. Lowin, C. Mattman, M. Hahne, and J. Tschopp, “Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes,” International Immunology, vol. 8, no. 1, pp. 57–63, 1996. View at Publisher · View at Google Scholar · View at Scopus
22. C. Schmaltz, O. Alpdogan, K. J. Horndasch, et al., “Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect,” Blood, vol. 97, no. 9, pp. 2886–2895, 2001. View at Publisher · View at Google Scholar · View at Scopus